These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 22864095

  • 1. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD, Bao W, Holloway J, Mann J, Rye AK, Brown DE.
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [Abstract] [Full Text] [Related]

  • 2. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL, Daw JR, Coley KC, Rayburg R.
    J Manag Care Pharm; 2010 Aug; 16(1):23-31. PubMed ID: 20044844
    [Abstract] [Full Text] [Related]

  • 3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 4. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.
    J Manag Care Pharm; 2010 Feb; 16(1):46-58. PubMed ID: 20131495
    [Abstract] [Full Text] [Related]

  • 5. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 6. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
    J Manag Care Pharm; 2010 Dec; 16(1):15-22. PubMed ID: 20044843
    [Abstract] [Full Text] [Related]

  • 7. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 8. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
    Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ.
    J Med Econ; 2012 Dec; 15(5):997-1018. PubMed ID: 22435648
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
    Lundeen K, Pfeiffenberger T, Jacobson Vann J, O'Brien T, Sampson C, Wegner S.
    J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J, Palivizumab Outcomes Registry Group.
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR, Masaquel AS, Weiner LB, Smith DM, Wade SW, Mahadevia PJ.
    BMC Pediatr; 2014 Oct 13; 14():261. PubMed ID: 25308481
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B, Steele S, Janes M, Pinelli J.
    Curr Med Res Opin; 2009 Jul 13; 25(7):1585-91. PubMed ID: 19469698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.